drugset
drugset / Trial / NCT04675242

Study Evaluating the Safety and Efficacy of NCX 4251 Ophthalmic Suspension for the Treatment of Blepharitis

NCT04675242 ↗

Phase 2 Completed 224 enrolled Nicox Ophthalmics, Inc.
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a multi-center, randomized, double-masked, placebo-controlled, Phase 2b trial evaluating the safety and efficacy of NCX 4251 (fluticasone propionate nanocrystal) Ophthalmic Suspension 0.1% QD for the treatment of acute exacerbations of blepharitis.

Timeline

Start
2020-12-14
Primary completion
2021-06-16
Completion
2021-06-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Fluticasone propionate Other / unclassified 0.1 % —

Indications

blepharitis